For HER2-altered NSCLC, clinical trials are conducted with antibody-drug conjugates, like T-DXd (Trastuzumab Deruxtecan), T-DM1 (Trastuzumab Emtansine), but also with TKIs, like Pyrotinib and Poziotinib (Uy et al., 2022[86]). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.